title: BK polyomavirus reactivation after reduced-intensity double umbilical cord blood cell transplantation.
abstract: Serial serum samples from 27 patients who underwent double umbilical cord blood transplantation (dUCBT) were analyzed for BK polyomavirus (BKPyV) DNA by real-time PCR and BKPyV-specific immune globulin by ELISA. Clinical data were collected on all patients. All pre-transplant sera had detectable anti-BKPyV IgG. Fifteen patients (56%) had detectable serum BKPyV DNA (median 8.9 × 10(4) copies/ml; range 4.1 × 10(3)-7.9 × 10(6) copies/ml) a median of 40 days (range, 27-733 days) after dUCBT, with highest viral loads on Day 100 assessment. The cumulative probability of developing BKPyV viremia by Day 100 was 0.52 (95% CI, 0.33-0.71). Six of 15 patients with BKPyV viremia experienced hemorrhagic cystitis by Day 100. By Day 100, there was a trend towards higher BKPyV viral loads in sera of patients with hemorrhagic cystitis than in those BKPyV viremic patients without hemorrhagic cystitis (p = 0.06). BKPyV viremia was associated with significantly higher anti-BKPyV IgM values at 6 months post-dUCBT (P = 0.003). BKPyV viremia occurs early after dUBCT and is associated with a detectable humoral immune response by 6 months post-dUBCT.
authors.affiliation: Division of Infectious Disease, Beth Israel Deaconess Medical Center, Boston, MA, USA; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA; Division of Hematology/Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.
authors.forename: Gowri
authors.initials: G
authors.lastname: Satyanarayana
authors.affiliation: Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.
authors.forename: Sarah P
authors.initials: SP
authors.lastname: Hammond
authors.affiliation: Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA; Division of Neurovirology, Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
authors.forename: Thomas A
authors.initials: TA
authors.lastname: Broge
authors.affiliation: Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA; Division of Neurovirology, Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
authors.forename: Matthew R
authors.initials: MR
authors.lastname: Mackenzie
authors.affiliation: Division of Developmental Neurovirology, Johns Hopkins University Medical Center, Baltimore, MD, USA.
authors.forename: Raphael
authors.initials: R
authors.lastname: Viscidi
authors.affiliation: Division of Neurovirology, Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
authors.forename: Ioannis
authors.initials: I
authors.lastname: Politikos
authors.affiliation: Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA; Division of Neurovirology, Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
authors.forename: Igor J
authors.initials: IJ
authors.lastname: Koralnik
authors.affiliation: Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.
authors.forename: Corey S
authors.initials: CS
authors.lastname: Cutler
authors.affiliation: Division of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USA.
authors.forename: Karen
authors.initials: K
authors.lastname: Ballen
authors.affiliation: Division of Neurovirology, Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
authors.forename: Vassiliki
authors.initials: V
authors.lastname: Boussiotis
authors.affiliation: Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.
authors.forename: Francisco M
authors.initials: FM
authors.lastname: Marty
authors.affiliation: Division of Infectious Disease, Beth Israel Deaconess Medical Center, Boston, MA, USA; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA; Division of Neurovirology, Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA, USA. Electronic address: ctan@bidmc.harvard.edu.
authors.forename: Chen Sabrina
authors.initials: CS
authors.lastname: Tan
mesh_terms: D000328:Adult; D000368:Aged; D064591:Allografts; D000914:Antibodies, Viral / Q000097:blood / Q000276:immunology; D001739:BK Virus / Q000502:physiology*; D036101:Cord Blood Stem Cell Transplantation; D004279:DNA, Viral / Q000097:blood / Q000276:immunology; D005260:Female; D005500:Follow-Up Studies; D019337:Hematologic Neoplasms / Q000097:blood / Q000276:immunology / Q000628:therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D027601:Polyomavirus Infections / Q000097:blood / Q000276:immunology; D014412:Tumor Virus Infections / Q000097:blood / Q000276:immunology; D014775:Virus Activation / Q000276:immunology*
chemical_list: D000914:Antibodies, Viral; D004279:DNA, Viral
keywords: BK polyomavirus; Hemorrhagic cystitis; Viral reactivation